Navigation Links
Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
Date:7/24/2014

CAMBRIDGE, Mass., July 24, 2014 /PRNewswire/ -- Blueprint Medicines (Blueprint), a leader in discovering highly selective kinase inhibitors for genomically defined cancer patients, today announced the appointment of Jeffrey Albers as chief executive officer (CEO). Mr. Albers joins Blueprint from Algeta ASA, where he served on the executive management team as U.S. president prior to the acquisition by Bayer. Mr. Albers succeeds Alexis Borisy, co-founder and interim CEO of Blueprint and Partner at Third Rock Ventures, who will remain an active member of the Board of Directors.

"Jeff's demonstrated excellence in commercial preparation and execution, business development and team building will be invaluable as we continue to grow Blueprint and advance our pipeline of highly selective kinase drugs into clinical development and ultimately the market," said Daniel Lynch, executive chairman of Blueprint. "While we look ahead to the Company's next phase, the Blueprint Board would like to thank Alexis for his many contributions to Blueprint's successes."

Mr. Albers brings more than 20 years of experience as a life sciences executive with a track record of leading fully integrated organizations, successfully launching products and achieving aggressive revenue targets. At Algeta, Mr. Albers oversaw the commercial and business functions during a period of exponential growth in staff and revenue. Before Algeta, Mr. Albers spent seven years at Genzyme, where he served most recently as vice president of the U.S. hematology & oncology business unit. Mr. Albers holds a Masters of Business Administration and a Juris Doctor from Georgetown University. 

"Leading and growing the talented Blueprint team as we take two potential breakthrough product candidates into clinical trials while continuing to build a strong, sustainable pipeline is extremely exciting," said Mr. Albers. "I look forward to lending my experience from oncology and rare genetic diseases to accelerate Blueprint's progress toward discovering, developing and commercializing transformative medicines for genomically defined patients in need."

About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint to rapidly develop potent, highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit BlueprintMedicines.com.

CONTACT:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212 362 1200
beth@sternir.com

Media Relations:
David Polk
Chandler Chicco Companies
310 309 1029
dpolk@chandlerchiccocompanies.com

Photo - http://photos.prnewswire.com/prnh/20140723/130038


'/>"/>
SOURCE Blueprint Medicines
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Worlds Only USDA Certified Organic and FDA Registered Homeopathic Medicines Guaranteed to Work
2. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
3. Warning: Not All Cold Sore Medicines Are Created Equal
4. Kick Off Summer Vacation With Five Simple Tips to Safely Store Medicines While Traveling
5. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
8. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
9. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
10. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... August 07, 2020 , ... Glewed ... original and professionally produced video content, today announced a partnership with award-winning director ... lives of real cancer patients. The first reality TV series of its kind, ...
(Date:8/5/2020)... ... ... In an informal poll of 150 fans, conducted by long-time Twins fan ... “Minnie and Paul” logo that is more racially and culturally sensitive and inclusive. The ... civil rights movement in the United States. The Minnesota Twins have never updated their ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... During COVID-19, An FDAnews Webinar, Wednesday, Aug. 19, 2020, 1:30 p.m.-3:00 p.m. ... is never simple and COVID-19 has made it more challenging. From COVID-19 ...
Breaking Medicine Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... CentrAlert, Inc. today announced ... access to essential COVID-19 information. Know NOW!, which is available for Apple ... unify them in one easy-to-use mobile application. , “When COVID-19 first hit, there was ...
(Date:8/5/2020)... ... August 04, 2020 , ... Total Spectrum, ... Spectrum Disorder (ASD) in Wisconsin, is delighted to announce the grand opening of ... of their newest center, Total Spectrum now proudly serves ten different locations across ...
(Date:8/5/2020)... , ... August 04, 2020 , ... Today, Power to ... Child Health Programs (AMCHP) with the 2020 Innovation Station Best Practice Award. The One ... and under what circumstances to get pregnant and have a child. One Key Question ...
(Date:8/3/2020)... ... August 03, 2020 , ... WorkBook6 – ... newest product, CoverageCoach. The site provides a simple and efficient way for Americans ... company sees CoverageCoach as an important expansion for the insurance marketing ecosystem, and ...
(Date:8/3/2020)... CHICAGO and FORT WORTH, Texas (PRWEB) , ... ... ... clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line ... arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). ...
Breaking Medicine News(10 mins):